Omeros (NASDAQ:OMER) posted its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04), Fidelity Earnings reports. The business had revenue of $4.61 million for the quarter, compared to analyst estimates of $3.07 million. During the same period last year, the firm earned ($0.16) EPS.
Shares of NASDAQ OMER traded down $3.00 during mid-day trading on Friday, reaching $13.02. 5,656,225 shares of the company’s stock traded hands, compared to its average volume of 613,109. The stock has a market capitalization of $793.47 million, a P/E ratio of -16.48 and a beta of 3.79. Omeros has a 1-year low of $8.36 and a 1-year high of $27.00.
A number of research firms have commented on OMER. ValuEngine cut shares of Omeros from a “buy” rating to a “hold” rating in a report on Saturday. Maxim Group restated a “buy” rating and issued a $32.00 price target on shares of Omeros in a report on Friday. HC Wainwright set a $34.00 price target on shares of Omeros and gave the stock a “buy” rating in a report on Wednesday, October 24th. BidaskClub upgraded shares of Omeros from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 17th. Finally, Zacks Investment Research upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $27.56.
In other news, VP Marcia S. Kelbon sold 7,529 shares of Omeros stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $25.75, for a total transaction of $193,871.75. Following the completion of the transaction, the vice president now directly owns 227,645 shares in the company, valued at $5,861,858.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.10% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Omeros (OMER) Announces Earnings Results” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/11/10/omeros-omer-announces-earnings-results.html.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Further Reading: Fundamental Analysis and Individual Investors
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.